Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa

References

• WHO. WHO validates elimination of mother-to-child transmission of HIV and syphilis in Cuba: World Health Organization; 2017 [cited 2017 Apr 19]. Available from: http://www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/en/
   Google Scholar
• UNAIDS. Prevention gap report. Geneva, Switzerland; 2016.
   Google Scholar
• WHO. Global health sector strategy on HIV 2016-2021. Towards ending AIDS. Geneva, Switzerland: World Health Organization; 2016.
   Google Scholar
• WHO. Global Health Observatory (GHO) data: prevention of mother-to-child transmission (PMTCT): World Health Organization; 2017 [cited 2017 07–23]. Available from: http://www.who.int/gho/hiv/epidemic_response/PMTCT_text/en/
   Google Scholar
• UNAIDS. Ending AIDS progress towards the 90-90-90 targets: global AIDS update 2017: joint United Nations Programme on HIV/AIDS (UNAIDS); 2017 [cited 2017 07–26]. Available from: http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf
   Google Scholar
• WHO. HIV/AIDS: data and statistics: World Health Organization; 2017 [cited 2017 07–25]. Available from: http://www.who.int/hiv/data/en/
   Google Scholar
• WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.
   Google Scholar
• WHO. New guidance on prevention of mother-to-child transmission of HIV and infant feeding in the context of HIV: World Health Organization; 2010 [cited 2017 Jun 06]. Available from: http://www.who.int/hiv/pub/mtct/PMTCTfactsheet/en/
   Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization; 2013.
   Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva, Switzerland: World Health Organization; 2016.
   Google Scholar
• UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive 2011–2015. Geneva: UNAIDS; 2011.
   Google Scholar
• Shapiro RL, Hughes M, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. New England J Med. 2010;362(24):2282–2294.
   PubMed Web of Science ®Google Scholar
• Taha TE, Li Q, Hoover DR, et al. Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. Jaids. 2011;57(4):319–325.
   Google Scholar
• Fowler MG, Coovadia H, Herron CM, et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 1999 2014;65(3):366.
   Web of Science ®Google Scholar
• Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet. 2012;379(9835):2449–2458.
   PubMed Web of Science ®Google Scholar
• Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240–249.
   PubMed Web of Science ®Google Scholar
• Fadare JO, Adeoti AO, Desalu OO, et al. The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):639–650.
   PubMed Web of Science ®Google Scholar
• Karnon J, Orji N. Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses. Health Policy Plan. 2016;31(8):1133–1141.
   PubMed Web of Science ®Google Scholar
• Malmstrom R, Godman B, Diogene E, et al. Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
   PubMed Web of Science ®Google Scholar
• Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707–722.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. New York, USA: Oxford University Press; 2006.
   Google Scholar
• Gopalappa C, Stover J, Shaffer N, et al. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. AIDS (London, England). 2014;28:S5–S14.
   PubMed Web of Science ®Google Scholar
• Ciaranello AL, Perez F, Engelsmann B, et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis. 2013;56(3):430–446.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Shimbo T, Miyano S, et al. Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. PLoS One. 2014;9(3):e90991.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Fasawe O, Avila C, Shaffer N, et al. Cost-effectiveness analysis of option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One. 2013;8(3):e57778.
   PubMed Web of Science ®Google Scholar
• Tweya H, Keiser O, Haas AD, et al. Comparative cost-effectiveness of option B+ for prevention of mother-to-child transmission of HIV in Malawi. AIDS (London, England). 2016;30(6):953–962.
   PubMed Web of Science ®Google Scholar
• VanDeusen A, Paintsil E, Agyarko-Poku T, et al. Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana. BMC Infect Dis. 2015;15(1):130.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Lamorde M, Hermans S, et al. Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World Health Organ. 2012;90(8):595–603.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402–408.
   PubMed Web of Science ®Google Scholar
• Paris V, Belloni A. Value in pharmaceutical pricing; 2013. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en
   Google Scholar
• Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2013;11(1):79–82.
   PubMedGoogle Scholar
• Faleiros DR, Álvares J, Almeida AM, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):257–266.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.
   PubMed Web of Science ®Google Scholar
• Tweya H, Gugsa S, Hosseinipour M, et al. Understanding factors, outcomes and reasons for loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi. Trop Med Int Health. 2014;19(11):1360–1366.
   PubMed Web of Science ®Google Scholar
• Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV infected pregnant and breastfeeding women (“Option B+”) in Malawi. AIDS (London, England). 2014;28(4):589.
   PubMed Web of Science ®Google Scholar
• Mirkuzie AH, Hinderaker SG, Sisay MM, et al. Current status of medication adherence and infant follow up in the prevention of mother to child HIV transmission programme in Addis Ababa: a cohort study. J Int AIDS Soc. 2011;14(1):50.
   PubMed Web of Science ®Google Scholar
• Geldsetzer P, Yapa HMN, Vaikath M, et al. A systematic review of interventions to improve postpartum retention of women in PMTCT and ART care. J Int AIDS Soc. 2016;19(1).
   Web of Science ®Google Scholar
• Godói IP, Santos AS, Reis EA, et al. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for future pricing considerations. Front Pharmacol. 2017;8.
   PubMed Web of Science ®Google Scholar
• Sachs J. Macroeconomics and health: Investing in health for economic development. In: Steele H, editor. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland 2001.
   Google Scholar
• Heath A, Manolopoulou I, Baio G. Estimating the expected value of partial perfect information in health economic evaluations using integrated nested laplace approximation. Stat Med. 2016;35(23):4264–4280.
   PubMed Web of Science ®Google Scholar
• Hicks C, Kashuba ADM, Walmsley S, editors. Update on Antiretroviral Treatment Failure and the Management of Treatment-Experienced HIV Infected Patients. Optimizing Therapy for Patients With Multidrug-Resistant HIV Review and Updates to the 2005 ICAAC Satellite Symposium, Management of Treatment-Experienced Patients. A Free CME/CE/CEU Monograph; 2006; New Orleans, Louisiana.
   Google Scholar
• Thompson A, Guthrie B, Payne K. Do pills have no ills? Capturing the impact of direct treatment disutility. PharmacoEconomics. 2016;34(4):333–336.
   PubMed Web of Science ®Google Scholar
• Net Monetary Benefit [online]. York: york health economics consortium; 2016 [cited 2017 06–17]. Available from: http://www.yhec.co.uk/glossary/net-monetary-benefit/
   Google Scholar